trending Market Intelligence /marketintelligence/en/news-insights/trending/j2KCzY3Iw5Wesq3aJDJO2w2 content esgSubNav
In This List

US FDA accepts Samsung Bioepis' application for Herceptin biosimilar

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA accepts Samsung Bioepis' application for Herceptin biosimilar

The U.S. Food and Drug Administration accepted Samsung Bioepis Co. Ltd.'s biologics license application for its biosimilar version of Roche Holding AG's breast cancer drug Herceptin.

If approved, SB3 will be commercialized in the U.S. by Merck & Co. Inc.

SB3 is Samsung Bioepis' first oncology biosimilar candidate submitted for regulatory approval in the U.S.